Research on display at Ohio State Lima
Apr. 1—LIMA — Several levels of academic inquiry will be on display during a research-focused day on Thursday, April 3, at Ohio State University at Lima, 4240 Campus Drive.
The Undergraduate Research Forum will be from 12:30 to 2:30 p.m. in the campus library.
Twenty-nine students will present their findings across a variety of topics including:
—Small mammals of South Asia
—Parasitoid flies
—Plants of the Tecumseh Interpretative Nature Preserve
—Colias butterflies
—Tree species of the Ohio State at Lima campus
—Microorganisms of the Miami-Erie Canal
—Bioassessment of the Lost Creek
—Narrative comprehension in preschoolers
—Smartphone usage patterns and suggestibility
—Executive functioning in children
Each student or group of students will display research findings on a poster and talk about their projects. Two students will also present their Second Year Transformational Experience Program projects.
At 1:30 p.m., an exceptional undergraduate student on campus with a successful record of research success will be awarded the 2025 Undergraduate Research Award, presented by Charles River Laboratories.
At 3 p.m., Dr. Virginia Tompkins will present "Examination of Factors Influencing Young Children's Narrative Comprehension," a study on the effects of race and gender on preschoolers' story comprehension in the Special Collections Room of the library.
Featured Local Savings
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
26-05-2025
- Forbes
Explaining Climate Change in 1,000 words
In a previous post, I argued that we need a new American narrative for talking about climate change. This is a necessary but not sufficient condition for creating a bipartisan consensus across our political divide in order to establish stable, long-term policies to the benefit of all Americans. These policies must, as I've also written about before, strike the right balance between affordability, security, resiliency, and carbon intensity. Crafting this narrative won't be easy. I've been thinking about it for a while but am far from ready to try writing even a first draft. So I decided to start with something simpler which is to write 1,000 words explaining climate change. The audience is American citizens who are not experts, who have different levels of knowledge and interest, and who range across the political spectrum. I made the arbitrary decision that anyone willing to read a piece with this title would tolerate up to 1,000 words. And that's probably stretching it given people's busy lives and how much people use social media to consume information today. My first crack at this is below. I found it extremely difficult to do. It is exactly 1,000 words (excluding the title). I'm sure there are many different ways to write such a piece. I'd love to see what others would come up with—in 1,000 words or less. ____________________________________________________________ According to the U.S. Energy Information Administration (EIA), fossil fuels provide about 83% of the energy needs in the United States. Nuclear and renewable energy each provide 9%, with 60% of the latter coming from biofuels. The production and consumption of fossil fuels generates carbon dioxide (CO2) which accumulates in the atmosphere and traps heat, a greenhouse effect (leading to the commonly used term 'greenhouse gas'). Since the beginning of the Industrial Revolution in the mid-18th century, the amount of CO2 (often called 'carbon emissions') has increased by 150%. It is difficult to put a precise figure on how much warming has taken place, but it is around 2°F or 1°C. Most of this warming has taken place over the past 40-50 years. Global warming has consequences for weather. According to NASA, global warming 'is impacting extreme weather across the planet. Record-breaking heat waves on land and in the ocean, drenching rains, severe floods, years-long droughts, extreme wildfires, and widespread flooding during hurricanes are all becoming more frequent and more intense.' If global warming continues, these effects will be even more severe, such as rising sea levels which could put many U.S. cities underwater by 2050. The year 2050 is often cited by those who study climate change, trying to anticipate its effects and how to mitigate and adapt to global warming. The general scientific consensus is that in order to avoid the most serious consequences of global warming, the temperature rise should be kept to around 2°C or 3.6°F by 2050. The issue of climate change due to global warming is an extremely complex one and it has become highly politicized in the U.S. While 72% of Americans believe that global warming is happening and 59% believe it's due to human activity, there is substantial variance in opinion about how serious of a problem it is now and will be in the future, what and how much should be done about it, who is responsible for dealing with it, and what costs should be incurred and by whom to address it. I have written about the vast divide between Republicans and Democrats, with Independents in the middle, (closer to Democrats). For many Republicans the very terms 'global warming' and 'climate change' are associated with a more general progressive Democratic political agenda which they don't support. Climate change is one of many topics about which there are strong feelings in our very polarized country. This makes it a very difficult issue from a public policy perspective, and we vividly see this when comparing the current administration to the previous one. At the heart of the debate in America about climate change is fossil fuels. Because they are a primary source of carbon emissions (although not the only one with animal agriculture, especially cattle, also being an important one) those who are most concerned about climate change think that fossil fuels should be replaced with renewable energy, especially solar and wind, as quickly as possible. Cost is a major consideration, especially if it is not competitive with fossil fuels, particularly compared to natural gas which the U.S. has in abundance. Even if renewables are cost competitive without government subsidies, these projects always face challenging permitting issues regarding the land for the project, often exacerbated by permitting issues to build the transmission lines to get the energy into the electrical grid. There are also challenges with reliability since battery storage technologies need further development. Nuclear power provides carbon-free baseload power but faces challenges of public acceptance, cost, and permitting. Geothermal can also provide very low-carbon baseload power but this technology is still being developed. Other technologies being developed are capturing carbon that is produced and removing carbon that is already in the atmosphere (direct air capture). Another important debate concerns the relative roles of the public and private sectors. Liberals typically advocate for strong government action such as subsidizing renewable energy, providing incentives to purchase electric vehicles and heat pumps, requiring companies to report on and reduce their carbon emissions, asking financial institutions to do the same regarding their portfolio companies, and putting a price on carbon. The concept of 'net zero,' meaning the company or financial institution is no longer contributing to an increase in atmospheric CO2 plays a prominent role. Conservatives who work on climate change put a greater emphasis on market forces and innovative, even breakthrough, technologies. Those who favor strong government action see global warming as a more immediate and pressing problem than do those who prefer market forces. A third important debate is the relative emphasis on mitigation (efforts to prevent global warming) vs. adaptation (dealing with the effects in various ways). Those who emphasize mitigation argue that costs incurred today are less than the costs of dealing with the problem in the future. Those more focused on adaptation argue the reverse. There are no simple answers here. While the effects of climate change exist today, it is still very difficult to know the extent to which extreme weather events are due to global warming vs. other factors. Constructing future scenarios far into the future (like 2100) in order to assess mitigation vs. adaptation strategies is extremely difficult and filled with uncertainty. Where does this leave the average American? Each person has to decide for themselves such things as how much time they want to spend learning about and engaging on this issue (e.g., through voting, community efforts, and expressing their views in various ways), how important it is in the total picture of their life, and what changes (if any) they want to make in their own lifestyles (such as diet and frequency and modes of transportation). People who have more money have the luxury of having more choices. Another important choice is the extent to which a person engages with others, including those who have a very different view. Whatever choices an individual person makes will have no effect on climate change. That said, America will benefit if everyone respects the choices that others make.
Yahoo
19-05-2025
- Yahoo
Humanized Mouse and Rat Model Market Report 2025 - Market to Hit USD 409.8 Million by 2030
Humanized mouse models dominate the market type segment, expected to maintain the fastest growth through 2030 due to their utility in drug discovery and immuno-oncology research. North America leads the market, primarily driven by U.S. advancements. Key players include Charles River Laboratories and The Jackson Laboratory. Growing demand for specialized testing and the rise of CROs & CDMOs present further opportunities. Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "Humanized Mouse and Rat Model Market by Type, Application, End User, and Region - Global Forecast to 2030" report has been added to report segments the market by type, application, end user, and region, covering core factors like drivers, challenges, and opportunities influencing growth. It provides a detailed analysis of leading players, examining their products, strategies, and recent developments. The global humanized mouse and rat model market is projected to grow from USD 276.2 million in 2025 to USD 409.8 million in 2030, reflecting a robust CAGR of 8.2%. This growth is driven by increased R&D investments in pharmaceutical and biopharmaceutical sectors. The expansion of R&D pipelines is increasing the demand for outsourcing analytical testing, heightened by concentrated research initiatives on rare diseases and orphan drugs. The expensive nature of in-house drug development further fuels this trend, along with technological advancements, novel drug discovery techniques, and a rising demand for specialized testing services. Humanized Mouse Model Segment Leads The market is divided into humanized mouse models and humanized rat models. In 2024, humanized mouse models dominated the revenue share and saw the fastest CAGR growth. The surge in demand for cell-based humanized mouse models is powering this segment's expansion, supporting applications in drug safety and efficacy analysis, long-term studies in immuno-oncology, infectious diseases, and graft-versus-host disease. Immunology & Infectious Diseases: A Key Segment The humanized mouse and rat model market is segmented by application into several areas, including oncology and neuroscience. The immunology & infectious diseases segment held the second-largest market share in 2024. Mouse models are pivotal in immunology and inflammation studies, facilitating detailed analyses of immunological processes through targeted alterations in the mouse genome. Pharmaceutical & Biotechnology Sector to Record Highest Growth Among end users, pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes are significant segments. Pharmaceutical & biotechnology companies dominated in 2024 due to increasing expenditure on innovative drug development and the shift towards personalized medicine. However, the CROs & CDMOs segment is predicted to have the highest growth, driven by rising outsourcing of preclinical studies and drug development activities. US Market Growth Leading the Way The market is categorized by geography into regions such as North America, Europe, and Asia Pacific. North America led in 2024, with the United States at the forefront, backed by substantial life sciences research funding and active research in mAbs and biosimilars. This dominance is also supported by a rising incidence of cancer. Competitive Landscape Key industry players include Charles River Laboratories, The Jackson Laboratory, Taconic Biosciences, JSR Corporation, Champions Oncology, and CLEA Japan Inc. Others are genOway, Inotiv, Janvier Labs, Altogen Labs, Vitalstar Biotechnology, Ingenious Targeting Laboratory, Reaction Biology, Harbour BioMed, Oncodesign Services, Pharmatest Services, Ozgene Pty Ltd., TransCure bioServices, Cyagen Biosciences, Aragen Life Sciences, GemPharmatech, and Biocytogen. Benefits of the Report: The report offers market leaders and new entrants close approximations of revenue numbers and valuable insights to enhance market positioning. It enables stakeholders to grasp market dynamics and devise effective strategies. Report Insights Include: Analysis of market drivers, like the increased use of humanized models in drug discovery. Detailed insights into product development and upcoming technologies. Comprehensive information on growth across varied regions. Exhaustive data on new products, untapped geographies, and market investments. In-depth competitive assessment of market leaders. Key Attributes: Report Attribute Details No. of Pages 255 Forecast Period 2025 - 2030 Estimated Market Value in 2025 276.2 million Forecasted Market Value by 2030 409.8 million Compound Annual Growth Rate 8.2% Regions Covered Global Key Topics Covered: Market Dynamics Drivers Rising Use of Humanized Models in Drug Discovery Research Emerging Preclinical Applications of Humanized Mouse Models Government-Funded Initiatives For Cancer Research Increasing R&D Activities in Pharmaceutical & Biotechnology Industry Restraints Introduction of FDA Modernization Act 2.0/3.0 Stringent Regulatory Compliance For Ethical Use of Animal Models Opportunities Growing Preference For Humanized PDX Models Emergence of Crispr in Biomedical Research Challenges Alternative Methods For Animal Testing Limitations of Humanized Mouse Models Company Profiles Charles River Laboratories The Jackson Laboratory Inotiv Genoway Taconic Biosciences, Inc. Jsr Corporation Champions Oncology, Inc. Janvier Labs Vitalstar Biotechnology Ingenious Targeting Laboratory Harbour Biomed Oncodesign Services Pharmatest Services Ozgene Pty Ltd. Clea Japan, Inc. Altogen Labs Reaction Biology Transcure Bioservices Cyagen Aragen Life Sciences Ltd. Biocytogen Gempharmatech For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
11-04-2025
- Yahoo
FDA to phase out animal testing with AI and lab-based models
The US Food and Drug Administration (FDA) has announced plans to begin replacing animal testing in drug development with 'more effective, human-relevant methods', including AI models and lab-based systems like organ-on-a-chip. The shift is grounded by the 2022 FDA Modernization Act, which for the first time authorised the use of non-animal alternatives in preclinical testing. The FDA said the new framework, initially targeting monoclonal antibodies (mAbs), aims to enhance drug safety, as well as reduce R&D costs and drug prices. mAbs form the backbone of many cancer, autoimmune, and infectious disease therapies. Under the plan, developers of investigational new drugs (INDs) are encouraged to submit data from new approach methodologies, which include computational models, organ-on-a-chip systems, and other advanced in vitro platforms. The agency will also begin accepting real-world safety data from countries with comparable regulatory standards, allowing it to assess previously studied drugs without repeating animal trials. While the timeline for full implementation remains unclear, the FDA said immediate changes would apply to IND submissions. A pilot programme will launch in the coming year, offering selected mAb developers the opportunity to use a primarily non-animal-based testing strategy under FDA oversight. FDA Commissioner Martin Makay called the move 'a paradigm shift in drug evaluation' that could accelerate access to treatments while improving animal welfare. William Blair analysts described the announcement as 'a statement of intent' rather than a binding regulatory overhaul. They noted that while the 2022 legislation allowed for non-animal testing, it did not commit to reducing or eliminating animal use. 'We expect these changes to be rolled out gradually over time and believe drug developers will still want to do at least some animal testing,' the analysts wrote. They flagged Charles River Laboratories – which derives around 20% of its revenue from non-human primate testing – as vulnerable. The company's shares dropped 28% following the news. In contrast, William Blair views the development as a long-term tailwind for Certara and Simulations Plus, which offer AI-driven and in silico preclinical models. Outside of regulatory circles, the announcement has drawn attention across the scientific community. Medical sciences professional Paniz Farshadyeganeh on LinkedIn said: 'Animal testing has long been a necessary—but often cruel and poorly regulated—part of research. With advances in patient-derived iPSCs and organ-on-a-chip technologies, we now have the potential to build better, more human-relevant models.' Organ-on-chip technologies have gained traction as new tools for studying human disease, with newer developments such as tumour-on-chip models enabling cancer drug screening. Last month, researchers from Heinrich Heine University Düsseldorf and biotech firm Dynamic42 created a pancreatic cancer chip model, which showed promising results in testing MSD's FDA-approved therapy Zolinza (vorinostat). In parallel, simulation cell technologies are gaining momentum. AstraZeneca, in partnership with biological simulation company Turbine, has been using AI-driven models of cancer cells to predict drug resistance mechanisms and identify viable combination therapies in blood cancers. "FDA to phase out animal testing with AI and lab-based models" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
